DCM Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
DCM Advisors's VRTX Position: Q4 2022 in Review
DCM Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2022, closing a stake of 2,566 shares — an estimated $743K sold.
DCM Advisors first reported a position in VRTX in Q2 2022 and held it in 2 quarters. The position peaked at $786K in Q2 2022. 1,222 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.
- DCM Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- DCM Advisors sold 2,566 Vertex Pharmaceuticals shares in Q4 2022, an estimated $743K.
- DCM Advisors first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 2 quarters.
- DCM Advisors's Vertex Pharmaceuticals position peaked at $786K in Q2 2022.
- 1,222 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.
Based on DCM Advisors's 13F filing for Q4 2022, filed 11 Sep 2023.